Oral Treatment of Obesity by GLP-1 and Its Analogs
Obesity is a multifaceted disease that significantly increases the risk of various chronic conditions. GLP-1R (co)-agonists first emerged as therapeutics
A forum for researchers, students and applicants in the field of cyclodextrin technology
Obesity is a multifaceted disease that significantly increases the risk of various chronic conditions. GLP-1R (co)-agonists first emerged as therapeutics
Soy peptides (SPs) have been extensively studied with an emphasis on their immune-boosting effects and production-associated bitterness. This associated bitterness
Previous studies have demonstrated that the solubility and biocompatibility of poorly water-soluble anti-cancer agents can be improved by complexation with
This post was written by Ibrahim Hussein. Cyclodextrin-based carriers have evolved beyond their traditional role as solubilizing agents toward ligand-targeted,
Cyclodextrins (CDs) have traditionally been recognized as excipients that enhance solubility and stability of drugs. However, growing evidence shows that
A review with 402 references Atherosclerosis is a complex cardiovascular disease driven by multiple factors, including aging, inflammation, oxidative stress,
Nanoemulsions, which are characterized by their nanometer-scale droplets, have gained significant attention in different fields, such as medicine, food, cosmetics,
Chronic pain (CP), including pain related to cancer, affects approximately 2 billion people worldwide, significantly diminishing quality of life and
Oral drug administration has become the most common and preferred mode of disease treatment due to its good medication adherence
The oral route stands out as the most commonly used method for drug administration, prized for its non-invasive nature, patient